In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.

[EX Q]: Tropical Forest and Coral Conservation Reauthorization Act of 2007 - (Sec. 2) Renames the Tropical Forest Conservation Act of 1998 as The Tropical Forest and Coral Conservation Act of 2007 (Act).

(Sec. 3) Includes tropical forests and coral reefs and associated coastal marine ecosystems within the scope of such Act. (Current law refers to tropical forests.)

(Sec. 4) Renames the Tropical Forest Facility as the Conservation Facility.

(Sec. 5) Makes developing countries with tropical forests or coral reefs eligible for benefits. (Current law refers to tropical forests.)

(Sec. 6) Authorizes U.S. government representation on the administering body that oversees the implementation of grants from a debt-for-nature swap or debt buy-back regardless of whether the United States is a party to any agreement between the eligible purchaser and the government of the beneficiary country.

(Sec. 7) Eliminates the requirement that the Enterprise for the Americas Board be consulted in negotiating a Conservation Agreement.

Requires U.S. government and beneficiary country government review of Conservation Fund grants in excess of $250,000.

(Sec. 8) Renames: (1) the Tropical Forest Agreement as the Conservation Agreement; and (2) the Tropical Forest Fund as the Conservation Fund.

(Sec. 9) Repeals Board authority to carry out activities under the Act.

(Sec. 10) Revises certain reporting dates.

(Sec. 11) Revises specified International Monetary Fund (IMF) criteria for country eligibility.

(Sec. 12) Authorizes FY2008-FY2010 appropriations. Increases obligations for program administration, monitoring, and auditing.
[EX A]: A bill to reauthorize the Tropical Forest Conservation Act of 1998 through fiscal year 2010, to rename the Tropical Forest Conservation Act of 1998 as the "Tropical Forest and Coral Conservation Act of 2007", and for other purposes.

[EX Q]: Bias Crimes Compensation Act of 1997 - Declares that all individuals within the United States, and its special maritime and territorial jurisdiction, shall have the right to be free from bias-motivated crimes of violence. 
Makes any person, including one who acts under color of any statute, ordinance, regulation, custom, or usage of any State, who deprives an individual of such right, liable to the individual injured, in a civil action in any court of competent jurisdiction, for compensatory damages of not less than $100,000, punitive damages, injunctive relief, declaratory relief, or any combination thereof. 
Specifies that nothing in this Act:  (1) entitles an individual to a claim herein for random acts of violence unrelated to bias or for acts that cannot be demonstrated, by a preponderance of the evidence, to be bias-motivated crimes of violence; and (2) requires a prior criminal complaint, prosecution, or conviction to establish the necessary elements of such a claim. 
Grants the Federal and State courts concurrent jurisdiction over actions brought under this Act. 
Prohibits a civil action in State court arising under this Act from being removed to U.S. district court. 
Authorizes the court to award attorney's fees to the prevailing party in cases brought under this Act, subject to specified limitations.
[EX A]: Bias Crimes Compensation Act of 1997

[EX Q]: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes.  To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.
[EX A]:
HEAL Act